Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Clinical evaluation of the Nanoduct sweat test system in the diagnosis of cystic fibrosis after newborn screening.

Vernooij-van Langen A, Dompeling E, Yntema JB, Arets B, Tiddens H, Loeber G, Dankert-Roelse J.

Eur J Pediatr. 2015 Aug;174(8):1025-34. doi: 10.1007/s00431-015-2501-0. Epub 2015 Feb 13.

PMID:
25678232
2.

National study of newborn hearing screening: programme sensitivity and characteristics of undetected children.

Korver AM, Konings S, Meuwese-Jongejeugd A, van Straaten HL, Uilenburg N, Dekker FW, Wever CC, Frijns JH, Oudesluys-Murphy AM; DECIBEL Collaborative study group.

B-ENT. 2013;Suppl 21:37-44.

PMID:
24383221
3.

Measuring free thyroxine levels in neonatal heel-prick samples.

Boelen A, van Veen M, Verkerk PH, Diependaal G, Loeber G, Elvers B, Endert E.

Clin Chim Acta. 2013 Aug 23;423:51-5. doi: 10.1016/j.cca.2013.04.004. Epub 2013 Apr 13.

PMID:
23588061
4.

Causes of permanent childhood hearing impairment.

Korver AM, Admiraal RJ, Kant SG, Dekker FW, Wever CC, Kunst HP, Frijns JH, Oudesluys-Murphy AM; DECIBEL-collaborative study group.

Laryngoscope. 2011 Feb;121(2):409-16. doi: 10.1002/lary.21377. Review.

PMID:
21271598
5.

Newborn hearing screening vs later hearing screening and developmental outcomes in children with permanent childhood hearing impairment.

Korver AM, Konings S, Dekker FW, Beers M, Wever CC, Frijns JH, Oudesluys-Murphy AM; DECIBEL Collaborative Study Group.

JAMA. 2010 Oct 20;304(15):1701-8. doi: 10.1001/jama.2010.1501.

PMID:
20959580
6.

DECIBEL study: Congenital cytomegalovirus infection in young children with permanent bilateral hearing impairment in the Netherlands.

Korver AM, de Vries JJ, Konings S, de Jong JW, Dekker FW, Vossen AC, Frijns JH, Oudesluys-Murphy AM; DECIBEL collaborative study group.

J Clin Virol. 2009 Dec;46 Suppl 4:S27-31. doi: 10.1016/j.jcv.2009.09.007.

PMID:
19836301
7.

Conference report: second conference of the Middle East and North Africa newborn screening initiative: Partnerships for sustainable newborn screening infrastructure and research opportunities.

Krotoski D, Namaste S, Raouf RK, El Nekhely I, Hindi-Alexander M, Engelson G, Hanson JW, Howell RR; MENA NBS Steering Committee.

Genet Med. 2009 Sep;11(9):663-8. doi: 10.1097/GIM.0b013e3181ab2277.

PMID:
19606054
8.

European best practice guidelines for cystic fibrosis neonatal screening.

Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A, Farrell M, Mehta A, Munck A, Pollitt R, Sermet-Gaudelus I, Wilcken B, Ballmann M, Corbetta C, de Monestrol I, Farrell P, Feilcke M, Férec C, Gartner S, Gaskin K, Hammermann J, Kashirskaya N, Loeber G, Macek M Jr, Mehta G, Reiman A, Rizzotti P, Sammon A, Sands D, Smyth A, Sommerburg O, Torresani T, Travert G, Vernooij A, Elborn S.

J Cyst Fibros. 2009 May;8(3):153-73. doi: 10.1016/j.jcf.2009.01.004. Epub 2009 Feb 26.

9.

A receptor-binding-based bioassay to determine the potency of a plasmid biopharmaceutical encoding VEGF-C.

Waerner T, Girsch T, Varga S, Huang L, Gornikiewicz A, Loeber G.

Anal Bioanal Chem. 2007 Dec;389(7-8):2109-13. Epub 2007 Oct 24.

PMID:
17957358
10.

A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity.

Stratowa C, Baum A, Castañon MJ, Dahmann G, Himmelsbach F, Himmler A, Loeber G, Metz T, Schnitzer R, Solca F, Spevak W, Tontsch U, von Rüden T.

Anticancer Drug Des. 1999 Oct;14(5):393-402.

PMID:
10766294
11.

Structure of a closed form of human malic enzyme and implications for catalytic mechanism.

Yang Z, Floyd DL, Loeber G, Tong L.

Nat Struct Biol. 2000 Mar;7(3):251-7.

PMID:
10700286
12.

Quality assurance and standardization: summary of the satellite meeting, Turku, Finland, 11-12 June 1999.

Webster D, Dhondt JL, Hannon WH, Loeber G, Torresani T.

Acta Paediatr Suppl. 1999 Dec;88(432):7-12.

PMID:
10626567
13.

Quality evaluation of newborn screening programs.

Loeber G, Webster D, Aznarez A.

Acta Paediatr Suppl. 1999 Dec;88(432):3-6.

PMID:
10626566
14.

Preliminary crystallographic studies of human mitochondrial NAD(P)(+)-dependent malic enzyme.

Bhargava G, Mui S, Pav S, Wu H, Loeber G, Tong L.

J Struct Biol. 1999 Aug;127(1):72-5.

PMID:
10479619
15.

Crystal structure of human mitochondrial NAD(P)+-dependent malic enzyme: a new class of oxidative decarboxylases.

Xu Y, Bhargava G, Wu H, Loeber G, Tong L.

Structure. 1999 Aug 15;7(8):R877-89.

PMID:
10477256
16.
17.

The use of genetically engineered cells in drug discovery.

Loeber G, Schnitzer R.

Genet Eng (N Y). 1998;20:249-66. Review. No abstract available.

PMID:
9666563
18.

DNA-binding and fluorescence properties of the DNA bis-intercalating purple oxazole dimer POPO-1.

Winter S, Loeber G.

J Biomed Opt. 1997 Jan;2(1):125-30. No abstract available.

PMID:
23014831
19.

Purification, cDNA cloning and heterologous expression of the human mitochondrial NADP(+)-dependent malic enzyme.

Loeber G, Maurer-Fogy I, Schwendenwein R.

Biochem J. 1994 Dec 15;304 ( Pt 3):687-92.

20.

Characterization of cytosolic malic enzyme in human tumor cells.

Loeber G, Dworkin MB, Infante A, Ahorn H.

FEBS Lett. 1994 May 16;344(2-3):181-6.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk